Angelini has been granted a patent for a pharmaceutical composition that combines trazodone and gabapentin to treat various types of pain, including chronic, inflammatory, and neuropathic pain. The combination of these drugs has a synergistic effect and is administered in specific dosage amounts and weight ratios. GlobalData’s report on Angelini gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Angelini, Peptide pharmacophores was a key innovation area identified from patents. Angelini's grant share as of September 2023 was 58%. Grant share is based on the ratio of number of grants to total number of patents.
A patent granted for a synergistic pain treatment composition
A recently granted patent (Publication Number: US11752147B2) discloses a method for treating pain by administering a combination of trazodone and gabapentin as the only active agents. The method is effective for treating various types of pain, including chronic pain, inflammatory pain, and neuropathic pain.
The method involves administering trazodone or a salt thereof in an amount equal to or lower than 0.2 mg/kg, and gabapentin or a salt or prodrug thereof in an amount equal to or lower than 2 mg/kg. The weight ratio of trazodone or salt thereof to gabapentin or salt or prodrug thereof is from 1:15 to 1:5.
Chronic pain is specifically mentioned as a type of pain that can be treated using this method. Inflammatory pain induced by conditions such as oedema, erythema, articular inflammation, osteoarthritis, rheumatoid arthritis, or arthrosis can also be effectively treated. Additionally, neuropathic pain induced by various factors including diabetes, cancer, immunodeficiency, trauma, ischemia, multiple sclerosis, sciatica, trigeminal neuralgia, fibromyalgia, or post-herpetic syndrome can be treated using this method.
In one specific embodiment, the method involves administering trazodone or a salt thereof in an amount equal to about 0.15 mg/kg and gabapentin or a salt or prodrug thereof in an amount equal to about 1.5 mg/kg. Another embodiment involves administering trazodone or a salt thereof and gabapentin or a salt or prodrug thereof in a trazodone to gabapentin weight ratio of about 1:10.
This patent provides a novel approach to pain treatment by combining trazodone and gabapentin as the only active agents. The specific dosages and weight ratios disclosed in the patent can be used to effectively treat chronic pain, inflammatory pain, and neuropathic pain induced by various underlying conditions. The method has the potential to offer improved pain management options for patients in need.
To know more about GlobalData’s detailed insights on Angelini, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
